199 related articles for article (PubMed ID: 20799722)
21. [Integrase inhibitors - new challenges for the treatment of HIV-1 infections].
Stock I
Med Monatsschr Pharm; 2013 Dec; 36(12):448-59; quiz 461-2. PubMed ID: 24450269
[TBL] [Abstract][Full Text] [Related]
22. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
[TBL] [Abstract][Full Text] [Related]
23. Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.
Smith RA; Raugi DN; Kiviat NB; Hawes SE; Mullins JI; Sow PS; Gottlieb GS;
AIDS; 2011 Nov; 25(18):2235-41. PubMed ID: 21971360
[TBL] [Abstract][Full Text] [Related]
24. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.
Fransen S; Gupta S; Danovich R; Hazuda D; Miller M; Witmer M; Petropoulos CJ; Huang W
J Virol; 2009 Nov; 83(22):11440-6. PubMed ID: 19759152
[TBL] [Abstract][Full Text] [Related]
25. Integrase inhibitors: a novel class of antiretroviral agents.
Schafer JJ; Squires KE
Ann Pharmacother; 2010 Jan; 44(1):145-56. PubMed ID: 20040702
[TBL] [Abstract][Full Text] [Related]
26. Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations.
Varadarajan J; McWilliams MJ; Hughes SH
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14747-52. PubMed ID: 23959861
[TBL] [Abstract][Full Text] [Related]
27. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness.
Hu Z; Kuritzkes DR
J Acquir Immune Defic Syndr; 2010 Oct; 55(2):148-55. PubMed ID: 20634701
[TBL] [Abstract][Full Text] [Related]
28. Impact of resistance mutations on inhibitor binding to HIV-1 integrase.
Chen Q; Buolamwini JK; Smith JC; Li A; Xu Q; Cheng X; Wei D
J Chem Inf Model; 2013 Dec; 53(12):3297-307. PubMed ID: 24205814
[TBL] [Abstract][Full Text] [Related]
29. Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes.
Quercia R; Dam E; Perez-Bercoff D; Clavel F
J Virol; 2009 Oct; 83(19):10245-9. PubMed ID: 19605484
[TBL] [Abstract][Full Text] [Related]
30. Bicyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.
Zhao XZ; Maddali K; Metifiot M; Smith SJ; Vu BC; Marchand C; Hughes SH; Pommier Y; Burke TR
Chem Biol Drug Des; 2012 Feb; 79(2):157-65. PubMed ID: 22107736
[TBL] [Abstract][Full Text] [Related]
31. Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.
Doyle T; Dunn DT; Ceccherini-Silberstein F; De Mendoza C; Garcia F; Smit E; Fearnhill E; Marcelin AG; Martinez-Picado J; Kaiser R; Geretti AM;
J Antimicrob Chemother; 2015 Nov; 70(11):3080-6. PubMed ID: 26311843
[TBL] [Abstract][Full Text] [Related]
32. HIV-1 subtype F integrase polymorphisms external to the catalytic core domain contribute to severe loss of replication capacity in context of the integrase inhibitor resistance mutation Q148H.
Aulicino PC; Momin Z; Rozenszajn M; Monzon A; Arazi-Caillaud S; Bologna R; Mangano A; Kimata JT
J Antimicrob Chemother; 2022 Sep; 77(10):2793-2802. PubMed ID: 35897124
[TBL] [Abstract][Full Text] [Related]
33. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
da Silva D; Van Wesenbeeck L; Breilh D; Reigadas S; Anies G; Van Baelen K; Morlat P; Neau D; Dupon M; Wittkop L; Fleury H; Masquelier B
J Antimicrob Chemother; 2010 Jun; 65(6):1262-9. PubMed ID: 20388636
[TBL] [Abstract][Full Text] [Related]
34. Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-Naive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1.
Sayan M; Yildirim FS; Akhan S; Karaoglan I; Akalin H
Curr HIV Res; 2022 Aug; 20(2):184-192. PubMed ID: 35240975
[TBL] [Abstract][Full Text] [Related]
35. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
Goethals O; Vos A; Van Ginderen M; Geluykens P; Smits V; Schols D; Hertogs K; Clayton R
Virology; 2010 Jul; 402(2):338-46. PubMed ID: 20421122
[TBL] [Abstract][Full Text] [Related]
36. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
Roquebert B; Damond F; Collin G; Matheron S; Peytavin G; Bénard A; Campa P; Chêne G; Brun-Vézinet F; Descamps D;
J Antimicrob Chemother; 2008 Nov; 62(5):914-20. PubMed ID: 18718922
[TBL] [Abstract][Full Text] [Related]
37. Raltegravir: the first HIV type 1 integrase inhibitor.
Hicks C; Gulick RM
Clin Infect Dis; 2009 Apr; 48(7):931-9. PubMed ID: 19231980
[TBL] [Abstract][Full Text] [Related]
38. Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.
Hassounah SA; Mesplède T; Quashie PK; Oliveira M; Sandstrom PA; Wainberg MA
J Virol; 2014 Sep; 88(17):9683-92. PubMed ID: 24920794
[TBL] [Abstract][Full Text] [Related]
39. Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.
Hassounah SA; Alikhani A; Oliveira M; Bharaj S; Ibanescu RI; Osman N; Xu HT; Brenner BG; Mesplède T; Wainberg MA
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923862
[TBL] [Abstract][Full Text] [Related]
40. Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages.
Marsden MD; Avancena P; Kitchen CM; Hubbard T; Zack JA
Antimicrob Agents Chemother; 2011 Aug; 55(8):3696-702. PubMed ID: 21628534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]